Glossary

QRISK3

QRISK3 is the tool NICE recommends for estimating a person's risk of a heart attack or stroke over the next 10 years, for people who don't already have cardiovascular disease. NICE recommends offering atorvastatin 20 mg to people with a QRISK3 score of 10% or more.

Clinically reviewed by Aisha Malik, Clinical Director (GPhC 2205843), on .

What it means in practice

NICE's guideline on cardiovascular disease risk assessment and reduction (NG238) recommends QRISK3 because its committee found it performed best among the tools assessed in a UK population. Primary care should use a systematic strategy to identify people likely to be at high risk, prioritising those whose estimated 10-year risk is 10% or more for a full formal assessment. NICE also says not to rule out a statin just because the score is under 10% if the person prefers to take one or there is concern that risk is underestimated. QRISK3 can overestimate risk if fields are left blank, so complete records matter. In a PCN, pharmacists often run statin and lipid searches, recalculate QRISK3 at reviews and have the shared decision conversation about starting a statin.

Good practice

  • Make sure blood pressure, cholesterol, smoking status and BMI are recorded before calculating QRISK3
  • Search for people with a recorded score of 10% or more who are not on a statin
  • Discuss risk in absolute terms so the person can make an informed decision
  • Record the decision, including when a person chooses not to take a statin

Questions

What QRISK3 score means a statin should be offered?

NICE (NG238) recommends offering atorvastatin 20 mg for primary prevention to people with a 10-year QRISK3 score of 10% or more, after discussing lifestyle changes and the person's preferences.

Can someone with a score below 10% have a statin?

Yes. NICE says not to rule out a statin because the score is below 10% if the person has an informed preference for taking one or there is concern that their risk is underestimated.

Sources

Checked against these sources on 19 November 2026.

  1. Cardiovascular disease: risk assessment and reduction, including lipid modification, NG238: recommendations (NICE)
  2. NG238 rationale and impact (NICE)

Remote clinical pharmacists, funded through ARRS.

Book a 30-minute call